

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

PTO/SB/08A (10-01)



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | To be assigned 1647 |
| Examiner Name | To be assigned B. Bunner |
| Attorney Docket Number | 3154-6317.21US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| BBB | - | FADESSI et al. Beta-Sheet Breaker Strategy for the Treatment of Alzheimer's Disease. Drug Development Res 56(2): 184-193, 2002. | - |
| BBB | - | BLONDELLE et al. Polyalanine-based Peptides as Models for Self-Associated Beta-Pleated-Sheet Complexes. Biochemistry 36: 8393-8400, 1997. | - |
| | | European Search Report, EP 00 97 6928, dated September 10, 2004. | |
| BBB | - | FAUCHERE et al., "Evaluation of the Stability of Peptides and Pseudopeptides as a Tool in Peptide Drug Design," Advances in Drug Research, 1992, pp. 127-159, vol. 23. | - |
| | - | GANTE, Joachim, "Peptidomimetics--Tailored Enzyme Inhibitors," Angewandte Chemie, 16 September 1994, pp. 1699-1720, vol. 33, no. 17. | - |
| | - | GOLABEK et al. The Interaction Between Apolipoprotein E and Alzheimer's Amyloid Beta-Peptide is Dependent on Beta-Peptide Conformation. J Biol Chem 271(18): 10602-10606, 1996. | - |
| | - | HETENYI et al. Computational Studies on the Binding of the Beta-Sheet Breaker (BSB) Peptides on Amyloid BetaA(1-42). J Molec Structure 542: 25-31, 2001. | - |
| | - | PERMANNE et al. Reduction of Amyloid Load and Cerebral Damage in a Transgenic Mouse Model of Alzheimer's Disease by Treatment with a Beta-Sheet Breaker Peptide. Faseb J. 16(8):860-862, 2002. | - |
| | - | PODUSLO et al., "Beta-Sheet Breaker Peptide Inhibitor of Alzheimer's Amyloidogenesis with Increased Blood-Brain Barrier Permeability and Resistance to Proteolytic Degradation in Plasma," Journal of Neurobiology, 5 June 1999, pp. 371-382, vol. 39, no. 3. | - |
| | - | SIGURDSSON et al. In vivo Reversal of Amyloid-Beta Lesions in the Rat Brain. J Neuropath Exp Neurol 59(1): 11-17, 2000 | - |
| | - | SOTO et al. Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent Beta-Sheet Conformation. Biochem Biophys Res Commun. 226(3): 672-680, 1996 | - |
| BBB | - | SOTO et al., "Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in a Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy," Nature Medicine, July 1998, pp. 822-826, vol. 4, no. 7. | - |

| | | | |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | Bridget E. Bunner | Date Considered | 11/10/05 |
|--------------------|-------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | To be assigned 1647 |
| Examiner Name | To be assigned B. Bunner |
| Attorney Docket Number | 3154-6317 2115 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| BEB | - | SOTO, Claudio, "Alzheimer's and Prion Disease as Disorders of Protein Conformation Implications for the Design of Novel Therapeutic Approaches," Journal of Molecular Medicine, May 1999, pp. 412-418, vol. 77 no. 5. | - |
| | - | SOTO, Claudio. Beta-Amyloid Disrupting Drugs. CNS Drugs 12(5): 347-356, 1999. | - |
| | - | SOTO, Claudio. Plaque Busters: Strategies to Inhibit Amyloid Formation in Alzheimer's Disease. Mol Med Today. 5(8):343-350, 1999. | - |
| BEB | - | WOOD et al. Prolines and Amyloidogenicity in Fragments of the Alzheimer's Peptide Beta/A4. Biochemistry 34:724-730, 1995. | - |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/706,540

Filed: November 4, 2000

Patent No: 6,689,753

Issue Date: February 20, 2004

For: B SHEET BREAKER PEPTIDE ANALOGS THAT INHIBIT B PLEATED SHEET FORMATION IN AMYLOID B -PEPTIDE, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | 1647 |
| Examiner Name | To be assigned B. Bunner |
| Attorney Docket Number | 3154-6317.2US |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| BEB | - | US-5,051,185 | 09-24-1991 | Watanabe et al. | |
| | - | US-5,216,127 | 06-01-1993 | Hiral et al. | |
| | - | US-5,230,996 | 07-27-1993 | Rath et al. | |
| | - | US-5,276,059 | 01-04-1994 | Caughey et al. | |
| | - | US-5,278,189 | 01-11-1994 | Rath et al. | |
| | - | US-5,449,663 | 09-12-1995 | Bicher | |
| | - | US-5,589,154 | 12-31-1996 | Anderson | |
| | - | US-5,824,808 | 04-29-1997 | Bicher | |
| | - | US-5,650,418 | 07-22-1997 | Rath et al. | |
| | - | US-5,700,447 | 12-23-1997 | Bucala et al. | |
| | - | US-5,733,524 | 03-31-1998 | Bucala et al. | |
| | - | US-5,733,933 | 03-31-1998 | Bucala et al. | |
| | - | US-5,780,615 | 07-14-1998 | Bucala et al. | |
| | - | US-5,801,200 | 09-01-1998 | Bucala et al. | |
| | - | US-5,869,534 | 02-09-1999 | Bucala et al. | |
| | - | US-5,935,927 | 08-10-1999 | Vitek et al. | |
| | - | US-5,958,883 | 09-28-1999 | Snow | |
| | - | US-6,001,331 | 12-14-1999 | Caprathe et al. | |
| | - | US-6,034,211 | 03-07-2000 | Kelly | |
| BEB | - | US-6,037,327 | 03-14-2000 | Castillo et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|--------------------|-----------------------|---|--------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | DE 193 35 902 A1 | 02-26-1999 | Intec Imundiagnostika GmbH | | |
| BEB | | 0 234 051 | 09-02-1987 | Stichting Centraal Laboratorium | | |
| | | 0 319 144 A1 | 06-07-1989 | Asahi Kasei Kogyo Kabushiki Kaisha | | |
| | | 0 494 848 A1 | 07-15-1992 | Kabi Pharmacia AB | | |
| | | EP 1 130 031 A1 | 09-05-2001 | Universitair Medisch Centrum Utrecht | | |
| | | EP 1 179 588 A1 | 02-13-2002 | Matsumoto | | |
| | | WO 91/18810 | 12-12-1991 | Olle Ljungqvist Medical AB | | |
| BEB | | WO 91/19488 | 12-26-1991 | Rath et al. | | |

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

11/18/05

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | 1647 |
| Examiner Name | To be assigned B. Bunner |
| Attorney Docket Number | 3154-6317.2US |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| BEB | - | US- 6,037,458 | 03-14-2000 | Hirai et al. | |
| | - | US- 6,136,548 | 10-24-2000 | Anderson | |
| | - | US- 6,340,783 B1 | 01-22-2002 | Snow | |
| | - | US- 6,399,314 B1 | 06-04-2002 | Krishnamurthy | |
| | - | US- 6,410,598 B1 | 06-25-2002 | Vitek et al. | |
| | - | US- 6,436,969 B1 | 08-20-2002 | Khalifah et al. | |
| | - | US- 6,462,171 B1 | 10-08-2002 | Soto-Jara et al. | |
| | - | US- 6,471,960 B1 | 10-29-2002 | Anderson | |
| | - | US- 2002/0133019 A1 | 09-19-2002 | Klunk et al. | |
| | - | US- 2002/0187157 A1 | 12-12-2002 | Jensen et al. | |
| | - | US- 2003/0017995 A1 | 01-23-2003 | Khalifah et al. | |
| | - | US- 2003/0050245 A1 | 03-13-2003 | Gebbink et al. | |
| | - | US- 6,537,969 B1 | 03-25-2003 | Blass | |
| | - | US- 2003/0072770 A1 | 04-17-2003 | McAnalley et al. | |
| | - | US- 2003/0086938 A1 | 05-08-2003 | Jensen et al. | |
| | - | US- 2003/0087407 A1 | 05-08-2003 | Soto-Jara et al. | |
| | - | US- 2003/0109435 A1 | 06-12-2003 | Prenner et al. | |
| | - | US- 2003/0118593 A1 | 06-26-2003 | Dan et al. | |
| | - | US- 2003/0176365 A1 | 09-18-2003 | Blass | |
| BEB | - | US- 2003/0236391 A1 | 12-25-2003 | Klunk et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|---|--------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| BEB | - | WO 92/11847 | 07-23-1992 | Kabi Pharmacia AB | | |
| | - | WO 94/01116 | 01-20-1994 | The Government of the United States | | |
| | - | WO 94/28909 | 12-22-1994 | Bicher | | |
| | - | WO 95/20979 | 08-10-1995 | Picower Institute for Medical Research | | |
| | - | WO 96/15799 | 05-30-1996 | Rutgers, The State University of New Jersey | | |
| | - | WO 96/39834 | 12-19-1996 | New York University | | |
| | - | WO 97/26919 | 07-31-1997 | Warner-Lambert Company | | |
| | - | WO 97/46547 | 12-11-1997 | Texas A & M University System | | |
| BEB | - | WO 98/06418 | 02-19-1998 | Mannatech, Inc. | | |

Examiner
Signature

Bridget C. Bunner

Date
Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1118/05

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

4

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | 1647 |
| Examiner Name | To be assigned B. Bunner |
| Attorney Docket Number | 3154-6317.2US |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|--------------------------|---|--------------------------------|--|---|----------------|
| | Country Code ³ - Number ⁴ - Kind Code ² (if known) | | | | |
| B02 | WO 99/02545 | 01-21-1999 | Novopharm Biotech Inc. | | |
| | WO 99/09999 | 03-04-1999 | University of Washington | | |
| | WO 99/21565 | 05-06-1999 | Cornell Research Foundation, Inc. | | |
| | WO 00/59493 | 10-12-2000 | Kansas University Medical Center | | |
| | WO 00/66717 | 11-09-2000 | Matsumoto | | |
| | WO 00/68263 | 11-16-2000 | Neurochem, Inc. | | |
| | WO 01/07474 A1 | 02-01-2001 | Stott | | |
| | WO 01/12598 A2 | 02-22-2001 | Trustees of Columbia University | | |
| | WO 01/50134 A2 | 07-12-2001 | American Cyanamid Co. | | |
| | WO 01/58476 A2 | 08-16-2001 | European Molecular Biology Laboratory | | |
| | WO 01/62284 A2 | 08-30-2001 | M & E Biotech A/S | | |
| | WO 01/62799 A2 | 08-30-2001 | Universitair Medisch Centrum Utrecht | | |
| | WO 02/16333 A2 | 02-28-2002 | University of Pittsburgh | | |
| | WO 03/006893 A2 | 01-23-2003 | Elan Pharmaceuticals, Inc. | | |
| B02 | WO 2004/004698 A2 | 01-15-2004 | Universitair Medisch Centrum Utrecht | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 4 | of | 4 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | 1647 |
| Examiner Name | To be assigned B. Dunner |
| Attorney Docket Number | 3154-6317.21US |

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Bridget C. Banner


Date
Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/726,366 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Claudio Soto-Jara |
| Group Art Unit | 1647 |
| Examiner Name | B. Bunner |
| Attorney Docket Number | 3154-6317.2US |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| Bob | - | US- 5,137,873 | 08-11-1992 | Yankner | - |
| Bob | - | US- 6,689,753 | 02-10-2004 | Soto-Jara | - |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------------|--------------------------|---|--------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| Bob | - | WO 96/28471 | 09-19-1996 | Pharmaceutical Peptides Incorporated | - | - |
| | - | WO 02/04954 A2 | 01-17-2002 | Applied Research Systems ARS Holding N.V. | - | - |
| | - | WO 03/050139 A2 | 06-19-2003 | Applied Research Systems ARS Holding N.V. | - | - |
| | - | WO 2004/005336 A2 | 01-15-2004 | Applied Research Systems ARS Holding N.V. | - | - |
| | - | WO 2004/050689 A2 | 06-17-2004 | Applied Research Systems ARS Holding N.V. | - | - |
| | - | WO 2004/083243 A1 | 09-30-2004 | Applied Research Systems ARS Holding N.V. | - | - |
| | - | WO 2004/096845 A2 | 11-11-2004 | Applied Research Systems ARS Holding N.V. | - | - |
| Bob | - | WO 2004/111652 A1 | 12-23-2004 | Applied Research Systems ARS Holding N.V. | - | - |
| | | | | | | |
| | | | | | | |

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/23/05

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/726,366 |
| | | Filing Date | December 3, 2003 |
| | | First Named Inventor | Claudio Soto-Jara |
| | | Group Art Unit | 1647 |
| | | Examiner Name | B. Bunner |
| Sheet 2 of 3 | Attorney Docket Number | 3154-6317.2US | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| EBB | - | BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, The Journal of Cell Biology, 1990, pp. 2129-38, Vol. 111. | - |
| | - | DOBELL et al., A Biotechnological Method Provides Access to Aggregation Competent Monomeric Alzheimer's 1-42 Residue Amyloid Peptide, Biotechnology, September 13, 1995, pp. 988-93, Vol. 13. | - |
| | - | FRASER et al., Conformation and Fibrillogenesis of Alzheimer A β Peptides with Selected Substitution of Charged Residues, J. Mol. Biol. 1994, pp. 64-73, Vol. 244. | - |
| | - | GHISO et al., Unifying Features of Systemic and Cerebral Amyloidosis, Molecular Neurobiology, 1994, pp. 49-64, Vol. 8, No. 1. | - |
| | - | HILBICH et al., Substitutions of Hydrophobic Amino-Acids Reduce the Amyloidogenicity of Alzheimers-Disease Beta-A4 Peptides, Journal of Molecular Biology, November 20, 1992, Vol. 228, No. 2. (abstract) | - |
| | - | KELLY et al., Alternative conformations of amyloidogenic proteins govern their behavior, 1996, pp. 11-17, Vol. 6. | - |
| | - | LAZAR et al., Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Molecular and Cellular Biology, Mar. 1988, pp. 1247-52, Vol. 8, No. 3. | - |
| | - | MERLINI et al., Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis, Proc. Natl. Acad. Sci., March 1995, pp. 2959-2963, Vol. 92, USA. | - |
| | - | PIKE et al., Structure-Activity Analyses of β -Amyloid Peptides: Contributions of the β 25-35 Region to Aggregation and Neurotoxicity, Journal of Neurochemistry, January 1995, pp. 253-65, Vol. 64, No. 1. | - |
| EBB | - | RUDINGER, Characteristics of the amino acids as components of a peptide hormone sequence, Jun. 1976, pp 1-7, In Peptide Hormones, Parsons (ed.), University Park Press, Baltimore. | - |

| | | | |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | Bridget E. Bunner | Date Considered | 11/10/05 |
|--------------------|-------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/23/05

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/726,366 |
| | | Filing Date | December 3, 2003 |
| | | First Named Inventor | Claudio Soto-Jara |
| | | Group Art Unit | 1647 |
| | | Examiner Name | B. Bunner |
| | | Attorney Docket Number | 3154-6317.2US |
| Sheet | 3 | of | 3 |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| BEB | - | SOTO et al., Abstract, Structural Determinants of the Alzheimers Amyloid Beta-Peptide, Journal of Neurochemistry, 1994, pp. 1191-98, Vol. 63. | - |
| | - | SOTO et al., Abstract, Two Conformational States of Amyloid Beta-Peptide - Implications for the Pathogenesis of Alzheimers-Disease, February 17, 1995, pp. 115-18, Vol. 186. | - |
| | - | SOTO et al., Fibrillogenesis of synthetic amyloid- β peptides is dependent on their initial secondary structure, Neuroscience Letters 200, 1995, pp. 105-08. | - |
| | - | SOTO et al., Inhibition of Alzheimer's Amyloidogenesis by Anti- β -sheet Peptides, <i>Alzheimer's Disease: Biology, Diagnosis and Therapeutics</i> , 1996, pp. 711-16. | - |
| | - | SOTO et al., The α -Helical to β -Strand Transition in the Amino-terminal Fragment of the Amyloid β -Peptide Modulates Amyloid Formation, The Journal of Biological Chemistry, 1995, pp. 3063-3067, Vol. 270, No. 7. | - |
| | - | TOMIYAMA et al., Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid β Protein in Vitro, Biochemical and Biophysical Research Communications, October 14, 1994, pp. 76-83, Vol. 204, No. 1. | - |
| | - | WILLE et al., Abstract, Prion protein amyloid: Separation of scrapie infectivity from PrP polymers, 1996, pp. 181-201, Vol. 199. | - |
| BEB | - | WISNIEWSKI et al., Peptides Homologous to the Amyloid Protein of Alzheimer's Disease containing a Glutamine for Glutamic acid substitution have Accelerated Amyloid Fibril Formation, Biochemical and Biophysical Research Communications, September 30, 1991, pp. 1247-54, Vol. 179, No. 3. | - |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|----------|
| Examiner Signature | Bridget E. Bunner | Date Considered | 11/10/05 |
|--------------------|-------------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

*Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.